EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Prognostic value of lactic dehydrogenase-to-albumin ratio in critically ill patients with acute respiratory distress syndrome: a retrospective cohort study

Fushuai Zhang, Mengyu Zhang, Zongge Niu, Lina Sun, Xiuhe Kang, Yiqing Qu

Journal of Thoracic Disease · 2024-01 · 16 (1) · 81-90

DOI: 10.21037/jtd-23-1238 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Thoracic Disease, 2024-01. Verfasst von Fushuai Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lactic dehydrogenase (LDH)-to-albumin ratio (LAR) was an independent risk factor for mortality in the patients with acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19), while the relationship among LAR and short-term, long-term, in-hospital mortalities of ARDS remains unclear. The current study aims to investigate the association between LAR and significant prognosis in patients with ARDS.

Methods

We conducted a retrospective cohort study and analyzed patients with ARDS on the Medical Information Mart for Intensive Care IV (MIMIC-IV) version 2.0 database. In the current study, 30-day mortality was defined as the primary outcome; 90-day mortality and in-hospital mortality were defined as secondary outcomes. Multivariate regression analysis, Kaplan-Meier curve analysis and subgroup analysis were performed to research the association between LAR and prognosis in patients with ARDS.

Results

A total of 358 critically ill patients with ARDS were enrolled in the current study. The mean age of the participants was 62.6±16.0 and the median of LAR was 14.3. According to the Kaplan-Meier curve analysis, the higher LAR group had a higher 30-day, 90-day and in-hospital mortalities. We also analyzed the 30-day mortality to receiver operating characteristic (ROC) curves by comparing the value between LAR and LAR + simplified acute physiology score II (SAPS II). The area under the curve (AUC) of the LAR group was 0.694 [95% confidence interval (CI): 0.634-0.754, P 30.9) were 2.00 (1.37, 2.92) and 2.50 (1.50, 4.15), respectively. Similar results were also observed for 90-day mortality and in-hospital mortality.

Conclusions

Elevated LAR levels are associated with increased 30- and 90-day mortalities, as well as in-hospital mortality in patients with ARDS, which means LAR levels may predict the mortalities of ARDS patients.

Schlagwörter

Stichwörter der Autor:innen

Acute respiratory distress syndrome (ARDS)intensive care unit (ICU)lactic dehydrogenase-to-albumin ratio (LAR)mortalityprognosis

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.

Zitieren

APA

Zhang, F., Zhang, M., Niu, Z., Sun, L., Kang, X., & Qu, Y. (2024). Prognostic value of lactic dehydrogenase-to-albumin ratio in critically ill patients with acute respiratory distress syndrome: a retrospective cohort study. Journal of Thoracic Disease, 16(1), 81-90. https://doi.org/10.21037/jtd-23-1238

Vancouver

Zhang F, Zhang M, Niu Z, Sun L, Kang X, Qu Y. Prognostic value of lactic dehydrogenase-to-albumin ratio in critically ill patients with acute respiratory distress syndrome: a retrospective cohort study. Journal of Thoracic Disease. 2024;16(1):81-90. doi:10.21037/jtd-23-1238

BibTeX
@article{Zhang2024,
  author = {Zhang, Fushuai and Zhang, Mengyu and Niu, Zongge and Sun, Lina and Kang, Xiuhe and Qu, Yiqing},
  title = {Prognostic value of lactic dehydrogenase-to-albumin ratio in critically ill patients with acute respiratory distress syndrome: a retrospective cohort study},
  journal = {Journal of Thoracic Disease},
  year = {2024},
  volume = {16},
  number = {1},
  pages = {81--90},
  doi = {10.21037/jtd-23-1238}
}
Kostenlos starten →